SCHEMBL20186936

SCHEMBL20186936

Cc1cccc([N+](=O)[O-])c1Nc1ncnc2c(C=O)csc12

nearest known ligand 0.45

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.45
MAPT P10636 3/20 0.45
EGFR P00533 6/20 0.41
MEN1 O00255 3/20 0.36
LCK P06239 1/20 0.36
CYP1A2 P05177 2/20 0.36
CYP3A4 P08684 2/20 0.36
CYP2C19 P33261 2/20 0.36
KCNMA1 Q12791 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
TSHR P16473 2/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
ERN1 O75460 1/20 0.34
ABCG2 Q9UNQ0 1/20 0.34
HSD17B10 Q99714 1/20 0.33
LMNA P02545 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20186938 0.91 KMT2A (0.44) KMT2AMAPTEGFRMEN1LCK
SCHEMBL20186931 0.86 KMT2A (0.47) KMT2AMAPTEGFRMEN1LCK
SCHEMBL20186906 0.83 MAPT (0.45) KMT2AMAPTEGFRMEN1LCK
SCHEMBL20200107 0.83 EGFR (0.48) KMT2AMAPTEGFRMEN1L3MBTL1
SCHEMBL20186943 0.74 RAF1 (0.45) KMT2AMAPTMEN1KCNMA1SMN1; SMN2
SCHEMBL20200109 0.73 EGFR (0.47) KMT2AMAPTEGFRMEN1L3MBTL1
SCHEMBL10373804 0.70 ERN1 (0.50) KMT2AMAPTMEN1CYP1A2CYP3A4
SCHEMBL18131701 0.68 TSHR (0.43) KMT2AMAPTMEN1LCKCYP1A2
SCHEMBL20200111 0.68 EGFR (0.48) KMT2AMAPTEGFRMEN1L3MBTL1
SCHEMBL21379013 0.68 MEN1 (0.41) KMT2AMAPTMEN1LCKCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10040803-B2 4-((2-acrylamidophenyl)amino)thieno[3,2-D]pyrimidine-7-carboxamide derivatives as protein kinase inhibitors KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2018-08-07 US disclosed
US-10040803-B2 4-((2-acrylamidophenyl)amino)thieno[3,2-D]pyrimidine-7-carboxamide derivatives as protein kinase inhibitors KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2018-08-07 US disclosed
US-10040803-B2 4-((2-acrylamidophenyl)amino)thieno[3,2-D]pyrimidine-7-carboxamide derivatives as protein kinase inhibitors KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2018-08-07 US disclosed
US-20180148459-A1 4-((2-ACRYLAMIDOPHENYL)AMINO)THIENO[3,2-D]PYRIMIDINE-7-CARBOXAMIDE DERIVATIVES AS PROTEIN KINASE INHIBITORS KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2018-05-31 US disclosed
US-20180148459-A1 4-((2-ACRYLAMIDOPHENYL)AMINO)THIENO[3,2-D]PYRIMIDINE-7-CARBOXAMIDE DERIVATIVES AS PROTEIN KINASE INHIBITORS KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2018-05-31 US disclosed
US-20180148459-A1 4-((2-ACRYLAMIDOPHENYL)AMINO)THIENO[3,2-D]PYRIMIDINE-7-CARBOXAMIDE DERIVATIVES AS PROTEIN KINASE INHIBITORS KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2018-05-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180148459-A1 4-((2-ACRYLAMIDOPHENYL)AMINO)THIENO[3,2-D]PYRIMIDINE-7-CARBOXAMIDE DERIVATIVES AS PROTEIN KINASE INHIBITORS CDK2, CDK2AP2, CDK2AP1 KMT2A 1357/4885MAPT 2542/4885EGFR 722/4885
US-10040803-B2 4-((2-acrylamidophenyl)amino)thieno[3,2-D]pyrimidine-7-carboxamide derivatives as protein kinase inhibitors CDK2, CDK2AP2, CDK2AP1 KMT2A 1357/4885MAPT 2542/4885EGFR 722/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.